InflaRx N.V.

Contributing Author

Recent Articles by InflaRx N.V.

Apr-09	InflaRx Reports New Mechanistic Data for Izicopan Supporting its Potential as a Best-in-Class C5aR Inhibitor IFRX +8.42% GlobeNewswire
Mar-31	InflaRx Announces Participation in the Raymond James 2026 Biotech Innovation Symposium IFRX +7.54% GlobeNewswire
Mar-30	InflaRx Highlights Clinical Activity of Vilobelimab in Pyoderma Gangrenosum in Late-Breaker Oral Presentation at 2026 American Academy of Dermatology Annual Meeting IFRX -8.79% GlobeNewswire
Mar-19	InflaRx Reports Full Year 2025 Results and Highlights Key Achievements and Expected Milestones IFRX GlobeNewswire
Mar-18	InflaRx Announces Late-Breaker Oral Presentation on Vilobelimab Phase 3 Results in Pyoderma Gangrenosum at 2026 American Academy of Dermatology Annual Meeting IFRX GlobeNewswire
Mar-13	InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement IFRX GlobeNewswire
Mar-12	InflaRx to Report Full Year 2025 Results on March 19, 2026 IFRX GlobeNewswire
Feb-26	InflaRx Announces Participation in the Leerink Partners Global Healthcare Conference IFRX GlobeNewswire
Jan-29	InflaRx Announces Participation in February Investor Conferences IFRX GlobeNewswire
Jan-08	InflaRx Announces Strategy Focused on Capital-Efficient Execution with Izicopan and Near-Term Value Creation IFRX -9.17% GlobeNewswire
Dec-30	InflaRx Provides Update on Phase 3 Data Analyses for Vilobelimab in Pyoderma Gangrenosum IFRX GlobeNewswire
Dec-11	InflaRx Announces International Nonproprietary Name of "Izicopan" for INF904 IFRX GlobeNewswire
Nov-10	InflaRx Reports Positive Phase 2a Data for INF904 in Hidradenitis Suppurative (HS) and Chronic Spontaneous Urticaria (CSU) IFRX +28.46% GlobeNewswire
Nov-07	InflaRx to Announce Topline Data from Phase 2a Clinical Trial of INF904 in Hidradenitis Suppurativa and Chronic Spontaneous Urticaria IFRX GlobeNewswire
Oct-21	InflaRx Announces Participation in the Guggenheim Securities 2nd Annual Healthcare Innovation Conference IFRX GlobeNewswire
Sep-12	InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement IFRX -14.29% GlobeNewswire
Aug-21	InflaRx Announces Participation in September Investor Conferences IFRX GlobeNewswire
Aug-07	InflaRx Reports Second Quarter 2025 Financial Results and Provides Business Update IFRX GlobeNewswire
Jul-31	InflaRx to Report Second Quarter 2025 Results on August 7, 2025 IFRX GlobeNewswire
Jul-11	InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement IFRX GlobeNewswire
May-28	InflaRx Announces Outcome of Interim Analysis for Vilobelimab Phase 3 Trial in Pyoderma Gangrenosum IFRX -59.86% GlobeNewswire
May-22	InflaRx to Participate in Upcoming Investor Conferences IFRX +7.69% GlobeNewswire
May-07	InflaRx Reports First Quarter 2025 Financial Results and Provides Business Update IFRX -7.45% GlobeNewswire

InflaRx N.V.

Recent Articles by InflaRx N.V.

Upgrade your Finviz experience